SCHEMBL4347228

SCHEMBL4347228

CN(CCOCCNc1c(N)cnc2ccccc12)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
PKM P14618 1/20 0.39
AAK1 Q2M2I8 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
GAA P10253 1/20 0.36
PDK2 Q15119 1/20 0.36
TOP2A P11388 3/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
POLB P06746 1/20 0.34
SLC2A1 P11166 1/20 0.34
APOBEC3A P31941 1/20 0.34
RAD52 P43351 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
MAPT P10636 2/20 0.34
RECQL P46063 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344723 0.85 CHRM2 (0.40) GBA1KMT2AMEN1PKMAAK1
SCHEMBL1039304 0.84 MEN1 (0.44) GBA1KMT2AMEN1PKMNPC1
SCHEMBL7171113 0.82 KMT2A (0.40) GBA1KMT2AMEN1PKMNPC1
SCHEMBL28680171 0.82 MEN1 (0.41) GBA1KMT2AMEN1PKMNPC1
SCHEMBL21106307 0.77 METAP2 (0.41) GBA1AAK1PDK2
SCHEMBL1232910 0.77 BCHE (0.52) KMT2AMEN1PKMNPC1RAB9A
SCHEMBL3170264 0.77 KMT2A (0.46) KMT2AMEN1PKMNPC1RAB9A
SCHEMBL1232778 0.76 STK17B (0.47) KMT2AMEN1PKMNPC1RAB9A
SCHEMBL1034070 0.76 BRD4 (0.47) KMT2AMEN1NPC1RAB9AGAA
SCHEMBL29475728 0.76 BRD4 (0.47) KMT2AMEN1NPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612083-B2 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-11-03 US disclosed
US-20080306252-A1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-11 US disclosed
US-7214675-B2 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-08 US disclosed
EP-1341790-B1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2007-02-14 EP disclosed
US-7132429-B2 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-07 US disclosed
US-7115622-B2 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-03 US disclosed
US-7078523-B2 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-07-18 US disclosed
US-7049439-B2 Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents 3M INNOVATIVE PROPERTIES CO. (US) 2006-05-23 US disclosed
EP-1343784-B1 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. 3M INNOVATIVE PROPERTIES CO (US) 2006-03-08 EP disclosed
US-20050234088-A1 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY 2005-10-20 US disclosed
EP-1341790-A2 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-10 EP disclosed
EP-1341792-A2 AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-10 EP disclosed
US-20030158192-A1 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY 2003-08-21 US disclosed
US-20030139441-A1 Sulfonamido ether substituted imidazoquinolines UBS AG, STAMFORD BRANCH 2003-07-24 US disclosed
US-20030130518-A1 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. 2003-07-10 US disclosed
US-20030096835-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-19 US disclosed
WO-2002046188-A2 AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed
WO-2002046191-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed
WO-2002046190-A2 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306252-A1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES IFNG, IRF3, IL2 GBA1 684/4885KMT2A 345/4885MEN1 3636/4885
US-20030158192-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG GBA1 2308/4885KMT2A 1389/4885MEN1 3193/4885
US-20030139441-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 GBA1 684/4885KMT2A 345/4885MEN1 3636/4885
US-20050234088-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG GBA1 2310/4885KMT2A 1421/4885MEN1 2953/4885
US-20030130518-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG GBA1 2308/4885KMT2A 1389/4885MEN1 3193/4885
US-20030096835-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 GBA1 2508/4885KMT2A 744/4885MEN1 1873/4885
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 GBA1 684/4885KMT2A 345/4885MEN1 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.